Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Cosmos Health (NASDAQ:COSM) announced that 4,874,126 Series B warrants, representing approximately 38% of its total outstanding warrants, expired unexercised at 5:00 p.m. New York City time on May 19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that 4,874,126 Series B warrants, representing approximately 38% of its total outstanding warrants, expired unexercised at 5:00 p.m. New York City time on May 19, 2026.
The warrants had a $0.95 exercise price. Their expiration issues no new shares, causes no dilution, reduces warrant overhang, and simplifies the capital structure.
Positive
- Expiration of 4,874,126 Series B warrants unexercised
- Elimination of approximately 38% of total outstanding warrants
- No new shares issued and no dilution to existing shareholders
- Reduced warrant overhang and simplified capital structure
Negative
- None.
Details
News Market Reaction – COSM
On May 21, the day this news came out, COSM closed 10.20% below the previous close. That session’s volume was 1.8x the stock’s average daily volume.
Data tracked by StockTitan Argus for the May 21 session.
Key Figures
- Series B warrant shares
- 4,874,126
- Series B warrants expired unexercised on May 19, 2026
- Outstanding warrant share share
- 38%
- Approximate share of total outstanding warrants represented by Series B
- Exercise price
- $0.95 per share
- Exercise price of expired Series B warrants
- Expiration time
- 5:00 p.m.
- New York City time on May 19, 2026 for Series B warrant expiry
Previous Crypto Reports
-
EIB advisory deal for up to €25M toward a €50M R&D program.
-
Company withdraws unused Form S-1 for a public offering with no securities sold.
-
Projects over $3.2M in incremental annual U.S. revenue from Fort18 within 12–18 months.
-
Announces U.S. launch of Fort18 men’s stamina supplement with supportive clinical data.
-
Projects over $2.5M in incremental annual U.S. revenue from Cur18 within 12–18 months.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrants financial
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
No dilution to existing shareholders
Reduction in total outstanding warrant overhang
Simplifies capital structure
CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.
The expired warrants carried an exercise price of
Their expiration eliminates this overhang with no new shares issued and no dilution to existing shareholders, while meaningfully simplifying the Company's capital structure going forward.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "The expiration of these warrants is a positive development for our shareholders. The elimination of 4.87 million warrant shares - representing almost
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.